Drug intelligence / Profile preview

WPV03

Development stage: Preclinical
Lead developer: Westlake Pharmaceuticals
Modality: Small Molecules

Overview

WPV03 is a small molecule antiviral candidate currently in the drug discovery stage at Westlake Pharmaceuticals. It is being developed for the treatment of viral infections, specifically those caused by coronaviruses such as SARS-CoV-2. While the specific mechanism of action and biological target for WPV03 have not yet been disclosed by the company, it represents a follow-on or complementary program to their more advanced 3CL protease inhibitor, WPV01. The asset is part of a broader pipeline of oral small molecules aimed at addressing respiratory viral threats.

Beyond the preview

Go deeper on WPV03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WPV03.

Explore the full profile